2024-10-21
Participating in CPHI Worldwid
Release Time: 2024-09-23
News Source: PharmaCompass
Author: SENOVA—Lucas
1、Lilly to invest additional US$ 1 bn in lreland to enhance Alzheimer's med production
Eli Lily has announced a significant US$ 1 bilion expansion of its manufacturing operations in lreland, bringing its total investment to US$ 2 bilion. The Limerick facility will focus on producing biologic active ingredients, including
donanemab for its recently approved Alzheimer's treatment Kisunla. This adds another 150 jobs to the previously
announced 300 jobs at the site.
2、 FDA approves Ebglyss for eczema
FDA has approved Eli Lily's new eczema drug, Ebglyss (lebrikizumab), based on three studies involving over 1,000
patients with moderate-to-severe eczema who were unable to control their symptoms with topical medicines or othel
systemic treatments. Unlike Dupixent (dupilumab), which requires twice-monthly dosing for adults, Ebglyss can be
dosed once-a-month, a feature analysts noted as attractive to both experts and patients. This approval marks the third FDA nod for Lilly's immunology unit in three years.
3、The approval of Novartis' Kisqali allows it to compete with Eli Lily's Verzenio (abemaciclilb) directly.
FDA has expanded the approval of Novartis' breast cancer drug Kisgali(ribociclilb) to include patients with earlier stages of the disease. Previously approved for breast cancer that has spread，Kisgali can now be used to treat HR-positive, HER2-negative early breast cancer, significantly broadening its reach. This expanded approval puts Kisgal in direct competition with Eli Lilly's Verzenio (abemaciclib), which has been a strong player in the early breast cancer treatment market, though it is limited to patients with nodal involvement. Kisaali. on the other hand, is available to a broader group of patients.
